SGFG
TBPH icon

Silver Grove Financial Group’s Theravance Biopharma TBPH Stock Holding History

Silver Grove Financial Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.31K Buy
+195
New +$3.23K ﹤0.01% 1383

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Silver Grove Financial Group's TBPH Position: Q2 2026 in Review

Silver Grove Financial Group opened a new position in Theravance Biopharma (TBPH) in Q2 2026: 195 shares worth $3.31K. The stake represents ﹤0.01% of the portfolio and ranks #1383 among its holdings.

179 funds tracked by Wall St. Rank hold TBPH as of Q2 2026.

  • Silver Grove Financial Group held 195 shares of Theravance Biopharma worth $3.31K as of Q2 2026.
  • Theravance Biopharma was a new Silver Grove Financial Group position in Q2 2026.
  • Theravance Biopharma made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #1383 holding.
  • 179 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.